1. Brierley JD, Gospodarowicz MK, Wittekind C (Hrsg) (2016) TNM classification of malignant tumours, 8. Aufl. Wiley-Blackwell, Hoboken
2. CWS Guidance guidance for risk adapted treatment of soft tissue sarcoma (STS) and soft tissue tumours in children adolescents, and young adults. https://www.kinderkrebsinfo.de/health_professionals/clinical_trials/pohkinderkrebsinfotherapiestudien/cws_guidance/index_eng.html . Zugegriffen: 28.07.2017
3. Demetri GD, Elias AD (1995) Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. In: Patel S, Benjamin RS (Hrsg) Hematology/Oncology Clinics of North America, Sarcomas Part II, Bd. 9. W.B. Saunders Company, Philadelphia, S 765–786
4. Demetri GD, von Mehren M, Jones RL et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34(8):786–793. https://doi.org/10.1200/JCO.2015.62.4734
5. ESMO European Sarcoma Network Group (2014) Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up. Ann Oncol 25(suppl 3):iii102–iii112. https://doi.org/10.1093/annonc/mdu254